Immunogenicity and Safety of the Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2008-2009 Formulation

NCT00718146 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

130

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza
Orthomyxoviridae Infections

Interventions

BIOLOGICAL: Split virion, inactivated Influenza vaccine
BIOLOGICAL: Split virion, inactivated Influenza vaccine

Sponsor

Sanofi Pasteur, a Sanofi Company